| Metric | Value (₹ Cr) | Q3 FY26 | Q4 FY25 |
|---|---|---|---|
| Revenue | 8.9K | 2.4% | 5.6% |
| Total Income | 9.0K | 1.6% | 5.3% |
| Expenditure | 7.7K | 3.3% | 7.4% |
| PBT | 1.3K | 3.4% | 5.4% |
| Net Profit | 920.84 | 1.2% | 2.0% |
| OPM | 19.80% | 0.04pp | 1.58pp |
| NPM | 10.27% | 0.03pp | 0.33pp |
| EPS | 15.86 | 1.2% | 1.9% |
Aurobindo Pharma FY26: Revenue Up 6.1% YoY to ₹33,653 Cr
21 May 2026 · 21 May, 8:52 pm
Summary
Aurobindo Pharma Limited announced a 5.6% year-on-year growth in Revenue from Operations, reaching ₹8,853 crore for Q4 FY26, with Net Profit increasing by 2.0% to ₹921 crore. For the full fiscal year 2026, revenue rose 6.1% to ₹33,653 crore, and net profit saw a modest 0.6% increase to ₹3,503 crore. The European business was a standout, crossing €1 billion in revenues for FY26 and growing 30.2% in Q4 FY26, alongside robust growth in Growth Markets. Vice-Chairman and Managing Director, Mr. K. Nithyananda Reddy, expressed confidence in the company's resilient business model and extensive product portfolio, attributing positive results to consistent volumes, improved operating efficiencies, and disciplined execution, while also highlighting ongoing investments for sustainable long-term value creation.
Key Highlights
- 1
Aurobindo Pharma Limited reported a 5.6% year-on-year increase in Revenue from Operations to ₹8,853 crore for the fourth quarter ended March 31, 2026.
- 2
Net Profit for Q4 FY26 grew modestly by 2.0% year-on-year, reaching ₹921 crore.
- 3
For the full fiscal year FY26, Revenue from Operations stood at ₹33,653 crore, representing a 6.1% increase over FY25, while Net Profit saw a marginal rise of 0.6% to ₹3,503 crore.
- 4
The European business achieved a significant milestone, crossing €1 billion in revenues for FY26, with Q4 FY26 revenues specifically soaring 30.2% year-on-year to ₹2,795 crore (EUR 261 million).
- 5
Revenue from Growth Markets also demonstrated strong performance, increasing by 24.7% year-on-year to ₹980 crore (USD 107 million) in Q4 FY26.
- 6
The company maintained a strong net cash position as of March 31, 2026, after completing the acquisition of Khandelwal laboratories' non-oncology business for USD 317 million, and generated $35 million in Free Cashflows during the quarter.
- 7
Aurobindo received final approval for 9 ANDAs from the USFDA during the quarter and launched 12 products, expanding its product portfolio.
Management Comments
Mr. K. Nithyananda Reddy
We are encouraged by our performance for the quarter and the year, reflecting the resilience of our business model and the strength of our extensive product portfolio. Consistent volumes coupled with improved operating efficiencies, and disciplined execution have contributed positively to our results. With ongoing investments in capacity expansion and the stabilization of recently commercialized facilities, we remain confident in our ability to support sustainable growth and create long-term value for our stakeholders.
Informational and educational content only. Not investment advice.